fulvestrant has been researched along with Peritoneal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Hossain, MM; Ishibashi, T; Ishikawa, M; Kanno, K; Kyo, S; Nakayama, K; Nakayama, S; Otsuki, Y; Razia, S; Sato, S; Shanta, K; Yamashita, H | 1 |
2 other study(ies) available for fulvestrant and Peritoneal Neoplasms
| Article | Year |
|---|---|
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
Topics: Cell Line; Cystadenocarcinoma, Serous; Female; Fulvestrant; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Receptors, Estrogen | 2022 |